|
|
Article: Clinic Roundup.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Affiris, of Vienna, Austria, initiated a Phase I clinical trial of Alzheimer's vaccine Affitope AD01. In the trial, up to 24 Alzheimer's patients will receive four vaccinations over a three-month period, with results monitored for six months. The trial initiation triggers a venture capital payment from Munich, Germany-based MIG-Fonds.
o Cougar Biotechnology Inc., of Los Angeles, said the FDA has allowed its investigational new drug application for CB3304 in the treatment of relapsed or refractory multiple myeloma. The company expects to begin a Phase I trial soon. CB3304 is an orally active, opium-derived alkaloid that inhibits microtubule dynamics, blocks cell ...